Legend Biotech of Nanjing reported positive data from a China Phase I/II trial of its CAR-T therapy in a heavily pre-treated population of multiple myeloma patients. In a trial that enrolled 57 patients, LCAR-B38M produced a complete response in 74% of the patients and an overall response rate of 88%. In 2017, Legend stunned the world with an overall response rate of over 90% in a small initial trial. At the end of 2017, Janssen Pharma paid $350 million upfront to partner the drug with Legend.
Source: China Biotoday
